Will plant-made biopharmaceuticals play a role in the fight against COVID-19?

Molecular farming – The slope of enlightenment

(2020) Rainer Fischer et al.   BIOTECHNOLOGY ADVANCES

Transient Expression of Dengue Virus NS1 Antigen in Nicotiana benthamiana for Use as a Diagnostic Antigen

(2020) Lívia É. C. Marques et al.   Frontiers in Plant Science

Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody

(2020) Xiaolong Tian et al.   Emerging Microbes & Infections

Engineering the interactions between a plant‐produced HIV antibody and human Fc receptors

(2019) Szymon Stelter et al.   PLANT BIOTECHNOLOGY JOURNAL

Immunogenicity and safety of a quadrivalent plant-derived virus like particle influenza vaccine candidate—Two randomized Phase II clinical trials in 18 to 49 and ≥50 years old adults

(2019) Stéphane Pillet et al.   PLoS One

Plant molecular farming of virus‐like nanoparticles as vaccines and reagents

(2019) Edward P. Rybicki   Wiley Interdisciplinary Reviews-Nanomedicine and Nanobiotechnology

In vitro and in vivo evaluation of a single chain antibody fragment generated in planta with potent rabies neutralisation activity

(2018) Waranyoo Phoolcharoen et al.   VACCINE

Plant-made polio type 3 stabilized VLPs—a candidate synthetic polio vaccine

(2017) Johanna Marsian et al.   Nature Communications

PotentIn VitroandIn VivoActivity of Plantibody Specific for Porphyromonas gingivalis FimA

(2016) Young-Suk Choi et al.   Clinical and Vaccine Immunology

Prime-boost vaccine strategy against viral infections: Mechanisms and benefits

(2016) Kimia Kardani et al.   VACCINE

Immunodominant SARS Coronavirus Epitopes in Humans Elicited both Enhancing and Neutralizing Effects on Infection in Non-human Primates

(2016) Qidi Wang et al.   ACS Infectious Diseases

Molecular pharming’s foot in the FDA’s door: Protalix’s trailblazing story

(2015) Tsafrir S. Mor   BIOTECHNOLOGY LETTERS

Emergency Ebola response: a new approach to the rapid design and development of vaccines against emerging diseases

(2015) Claire M Tully et al.   LANCET INFECTIOUS DISEASES

Animal models for SARS and MERS coronaviruses

(2015) Lisa M Gretebeck et al.   Current Opinion in Virology

The use of quantitative structure–activity relationship models to develop optimized processes for the removal of tobacco host cell proteins during biopharmaceutical production

(2013) J.F. Buyel et al.   JOURNAL OF CHROMATOGRAPHY A

Predictive models for transient protein expression in tobacco (Nicotiana tabacum L.) can optimize process time, yield, and downstream costs

(2012) J.F. Buyel et al.   BIOTECHNOLOGY AND BIOENGINEERING